Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit?

Publisher： Karger

E-ISSN： 1421-9786|20|4|239-244

ISSN： 1015-9770

Source： Cerebrovascular Diseases, Vol.20, Iss.4, 2005-09, pp. : 239-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Centenarian Stroke Treated with Tissue-Type Plasminogen Activator

By  

Cerebrovascular Diseases, Vol. 13, Iss. 4, 2002-05 ,pp. : 285-287

Karger

Access to resources Recommend Favorite

Intravenous Thrombolysis in German Stroke Units before and after Regulatory Approval of Recombinant Tissue Plasminogen Activator

By  

Cerebrovascular Diseases, Vol. 22, Iss. 5-6, 2006-11 ,pp. : 429-431

Karger

Access to resources Recommend Favorite

Low-Dose Tissue Plasminogen Activator and Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Review

By  

Cerebrovascular Diseases, Vol. 36, Iss. 3, 2013-10 ,pp. : 161-166

Karger

Access to resources Recommend Favorite

Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale

By  

Interventional Neurology, Vol. 6, Iss. 1-2, 2016-10 ,pp. : 25-30

Karger

Access to resources Recommend Favorite

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer

By  

Case Reports in Neurology, Vol. 6, Iss. 3, 2014-10 ,pp. : 238-242

Karger

Access to resources Recommend Favorite